Durvalumab (Imfinzi®) is indicated for for the treatment of locally advanced, unresectable Non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT)1.
| NCPE Assessment Process | Ongoing |
| Rapid review commissioned | 29/03/2019 |
| Rapid review completed | 29/04/2019 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/05/2019 |
| Pre-submission consultation with Applicant | 10/06/2019 |
| Submission received from Applicant | 30/08/2019 |
| Current Status | Submission received from Applicant |